94 related articles for article (PubMed ID: 30070630)
1. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.
Diez-Perez A; Naylor KE; Abrahamsen B; Agnusdei D; Brandi ML; Cooper C; Dennison E; Eriksen EF; Gold DT; Guañabens N; Hadji P; Hiligsmann M; Horne R; Josse R; Kanis JA; Obermayer-Pietsch B; Prieto-Alhambra D; Reginster JY; Rizzoli R; Silverman S; Zillikens MC; Eastell R;
Osteoporos Int; 2017 Mar; 28(3):767-774. PubMed ID: 28093634
[TBL] [Abstract][Full Text] [Related]
2. Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region.
Wu CH; Chang YF; Chen CH; Lewiecki EM; Wüster C; Reid I; Tsai KS; Matsumoto T; Mercado-Asis LB; Chan DC; Hwang JS; Cheung CL; Saag K; Lee JK; Tu ST; Xia W; Yu W; Chung YS; Ebeling P; Mithal A; Ferrari SL; Cooper C; Lin GT; Yang RS
J Clin Densitom; 2021; 24(1):3-13. PubMed ID: 31010789
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of teriparatide in in improving healing rates and bone-turnover markers of osteoporotic hip fracture: a meta-analysis.
Luo L; Lin J; Ma W; Fan J
J Pak Med Assoc; 2024 Apr; 74(4):741-751. PubMed ID: 38751272
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE.
Black DM; Thompson AR; Eastell R; Bouxsein ML
Lancet Diabetes Endocrinol; 2024 Jun; 12(6):371-373. PubMed ID: 38677307
[No Abstract] [Full Text] [Related]
5. The Use of Bone-Turnover Markers in Asia-Pacific Populations.
Vasikaran S; Thambiah SC; Tan RZ; Loh TP;
Ann Lab Med; 2024 Mar; 44(2):126-134. PubMed ID: 37869778
[TBL] [Abstract][Full Text] [Related]
6. Insight into the potential of bone turnover biomarkers: integration in the management of osteoporosis and chronic kidney disease-associated osteoporosis.
Brouwers P; Bouquegneau A; Cavalier E
Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):149-156. PubMed ID: 38804196
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Rand MS; Eiken PA; Jørgensen NR
Ugeskr Laeger; 2024 Jan; 186(5):. PubMed ID: 38327195
[TBL] [Abstract][Full Text] [Related]
8. PoCOsteo: generic novel platform for bone turnover marker measurement & monitoring.
Khashayar P; Lopes P; Ragaert P; Hoogenboom R; Latta D; Gransee R; Lenartowicz D; Biggs P; Etxebarria I; Luegger B; Obermayer-Pietsch B; Dimai HP; Vanfleteren J
Anal Methods; 2024 May; 16(21):3337-3348. PubMed ID: 38738371
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover markers: Emerging tool in the management of osteoporosis.
Shetty S; Kapoor N; Bondu JD; Thomas N; Paul TV
Indian J Endocrinol Metab; 2016; 20(6):846-852. PubMed ID: 27867890
[TBL] [Abstract][Full Text] [Related]
10. The Influences of Macronutrients on Bone Mineral Density, Bone Turnover Markers, and Fracture Risk in Elderly People: A Review of Human Studies.
Je M; Kang K; Yoo JI; Kim Y
Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892460
[TBL] [Abstract][Full Text] [Related]
11. Sirtuins: exploring next-gen therapeutics in the pathogenesis osteoporosis and associated diseases.
Waykar TR; Mandlik SK; Mandlik DS
Immunopharmacol Immunotoxicol; 2024 Jun; 46(3):277-301. PubMed ID: 38318808
[TBL] [Abstract][Full Text] [Related]
12. Bone remodeling markers: monitoring the changing bone.
Varo N
Adv Lab Med; 2024 Mar; 5(1):1-3. PubMed ID: 38634082
[No Abstract] [Full Text] [Related]
13. Bone mineral density and bone mineral content among female elite athletes.
Bellver M; Del Rio L; Jovell E; Drobnic F; Trilla A
Bone; 2019 Oct; 127():393-400. PubMed ID: 31271933
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of Osteoporosis: An Update.
Parveen B; Parveen A; Vohora D
Endocr Metab Immune Disord Drug Targets; 2019; 19(7):895-912. PubMed ID: 30727928
[TBL] [Abstract][Full Text] [Related]
15. Bone turnover marker monitoring in osteoporosis treatment response.
Tan RZ; Loh TP; Vasikaran S
Eur J Endocrinol; 2020 Jun; 183(1):C5-C7. PubMed ID: 32504486
[No Abstract] [Full Text] [Related]
16. Bone turnover: Biology and assessment tools.
Szulc P
Best Pract Res Clin Endocrinol Metab; 2018 Oct; 32(5):725-738. PubMed ID: 30449551
[TBL] [Abstract][Full Text] [Related]
17. Murine Myoblasts Exposed to SYUIQ-5 Acquire Senescence Phenotype and Differentiate into Sarcopenic-Like Myotubes, an In Vitro Study.
Gerosa L; Malvandi AM; Gomarasca M; Verdelli C; Sansoni V; Faraldi M; Ziemann E; Olivieri F; Banfi G; Lombardi G
J Gerontol A Biol Sci Med Sci; 2024 Apr; 79(4):. PubMed ID: 38267369
[TBL] [Abstract][Full Text] [Related]
18. Serum Metabolite Profile Associated with Sex-Dependent Visceral Adiposity Index and Low Bone Mineral Density in a Mexican Population.
Palacios-González B; León-Reyes G; Rivera-Paredez B; Ibarra-González I; Vela-Amieva M; Flores YN; Canizales-Quinteros S; Salmerón J; Velázquez-Cruz R
Metabolites; 2021 Sep; 11(9):. PubMed ID: 34564420
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring anti-osteoporotic therapy: bone mineral density or markers of bone turnover].
Pedersen SB; Rand MS; Eiken PA; Jørgensen NR
Ugeskr Laeger; 2018 Aug; 180(32):. PubMed ID: 30070630
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
